Endosonography
ProcedureComplete endosonographic mediastinal staging is performed in 2 steps:
- Systematic EBUS (airways)
- Systematic EUS-B (esophagus)
Other names: EBUS, EUS-B
NCT Number: NCT02014324
Rationale: Lung cancer is the most commonly diagnosed cancer worldwide and is the most frequent cause of cancer death. Accurate staging is important because it directs treatment and prognosis. Mediastinal staging can be done by both EBUS-TBNA and EUS-FNA. These two techniques have a complementary diagnostic range and the combined procedure is suited for assessment of almost the entire mediastinum. In practice, when mediastinal tissue staging is indicated, endoscopists often perform either an EBUS or an EUS investigation (instead of the combined procedure). Second, frequently only one or two, by imaging suspected lymph node stations, are sampled (ie. targeted approach).
Objectives: main and secondary:
1. Complete endosonographic (combined endobronchial and esophageal) staging using a single EBUS scope improves locoregional staging (N2, N3, T4) versus EBUS staging alone. 2. Systematic mediastinal staging results in improved locoregional staging compared to PET-CT directed assessment of the mediastinum (ie targeted approach).
Study population: Patients with potentially operable and resectable NSCLC are eligible if there is an indication for mediastinal nodal sampling. Patients have an indication for EBUS-TBNA.
Intervention: Patients will undergo an EBUS investigation followed by EUS-B in the same session. During this single scope procedure, lymph nodes that are suspected on prior CT-PET imaging and on subsequent ultrasound are sampled.
Main study endpoint: The main study parameter is the sensitivity for locoregional disease (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in comparison with EBUS staging alone.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Onze-Lieve-Vrouwen-Ziekenhuis, Aalst, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Complete endosonographic mediastinal staging is performed in 2 steps:
Other names: EBUS, EUS-B
Time frame: from inclusion untill either pathological proof of mediastinal metastases by endospnography or 1 week after surgical verification
Sensitivity is defined as number of true positives (pathologic proof of a nodal metastases) divided by the number of true positives and false negatives (thoracotomy with nodal dissection is the reference standard to detect false negatives).
The main study parameter is the sensitivity for locoregional disease (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in comparison with EBUS staging alone.
In the event of pathological proof of mediastinal metastases (N2/N3) by endosonography patients are classified as having locally advanced disease (stage III) and the study stops. When no mediastinal metastases are found by endosonography, surgical verification will take place (reference standard).
Time frame: from inclusion untill either pathological proof of mediastinal metastases by endosonography or 1 week after surgical verification
Sensitivity for locally advanced disease (N2-3 metastases, T4) of systematic assessment and sampling of mediastinal lymph nodes in comparison to PET-CT directed assessment of the mediastinum (ie targeted approach).
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Complete Endosonographic Staging of Lung Cancer: a Systematic Single Scope Approach
Acronym: SCORE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02639026
Breast Cancer, Breast Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04772989
Advanced Solid Tumor, Blood Protein Disorders
Los Angeles, California, United States
View Trial DetailsNCT02988817
Adnexal Diseases, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT02456246
Bronchial Neoplasms, Carcinoma, Bronchogenic
Toronto, Ontario, Canada
View Trial Details